中国P站

Reactive Oxygen Species; ROS; Cancer; Redox Balance; Therapeutic Strategies; Ferroptosis; Cancer Stem Cells; Drug Repurposing; Oxidative Stress; Tumor Microenvironment

Introduction

This review emphasizes that ROS are not solely damaging agents; physiologically, they participate in vital cellular signaling pathways. However, in cancer, a skewed redox balance drives pathological functions like proliferation and metastasis. Understanding this dual role is crucial for developing therapies that either boost ROS to induce cell death or scavenge excess ROS to protect healthy cells, highlighting a critical distinction between beneficial and detrimental ROS levels [1].

Cancer cells often exhibit elevated baseline ROS levels compared to normal cells, yet they manage to adapt and survive. This study delves into how this altered ROS homeostasis dictates cell fate, promoting survival or inducing death depending on the cellular context and the degree of oxidative stress. It underscores that manipulating this delicate balance is a promising strategy for targeted cancer therapies [2].

This work explores the exciting potential of repurposing existing FDA-approved drugs that modulate ROS metabolism for cancer treatment. It highlights specific biochemical pathways these drugs influence, either by increasing ROS to trigger cancer cell death or by dampening ROS to reduce chemotherapy resistance. This approach offers a faster, safer route to new cancer therapies by leveraging known drug safety profiles [3].

ROS play a remarkably complex dual role in cancer progression, acting as both instigators and suppressors of tumor growth depending on their concentration and cellular location. This article dissects the underlying mechanisms, from physiological signaling that can be hijacked by cancer cells to the biochemical pathways that lead to oxidative stress and cell death, paving the way for more nuanced therapeutic strategies [4].

This paper highlights the intricate biochemical relationship between ROS and ferroptosis, an iron-dependent form of regulated cell death, in the context of cancer. It explains how modulating ROS levels can specifically induce ferroptosis in cancer cells, offering a new avenue for targeted therapy by exploiting cancer cells' altered iron metabolism and oxidative vulnerabilities [5].

Targeting the redox system in cancer therapy involves manipulating the balance of ROS generation and scavenging, a strategy moving from fundamental molecular mechanisms to clinical trials. This review details how drugs targeting specific antioxidant enzymes or ROS-producing pathways can selectively kill cancer cells, reflecting a sophisticated understanding of their distinct physiological and biochemical dependencies [6].

This article focuses on therapeutic strategies that deliberately induce ROS accumulation to trigger cancer cell death, leveraging the inherent oxidative stress in malignant cells. It outlines various biochemical mechanisms by which these inducers operate, discussing their potential in clinical settings while also addressing the physiological challenges of selectively targeting cancer cells without harming healthy tissues [7].

Cancer stem cells (CSCs) are particularly resistant to conventional therapies, and their redox state plays a crucial role in this resistance and their self-renewal capacity. This paper explores the biochemical machinery governing ROS levels in CSCs, illustrating how targeted redox modulation can influence their physiological functions, potentially sensitizing them to existing treatments and overcoming therapy resistance [8].

This article investigates the complex interplay between ROS signaling and ferroptosis in immune cells within the tumor microenvironment. It details how ROS-mediated events impact immune cell function, either promoting or inhibiting anti-tumor immunity, underscoring the physiological significance of redox balance for effective immune surveillance and response against cancer [9].

ROS exhibit a truly paradoxical role in cancer: at low to moderate levels, they often promote tumor growth, survival, and metastasis, acting as signaling molecules. Yet, excessively high ROS levels can trigger cell death pathways. This review dissects these contrasting physiological and biochemical effects, highlighting how understanding this duality is key to developing precise ROS-modulating cancer therapies [10].

Description

Reactive Oxygen Species (ROS) exhibit a truly complex and often paradoxical role in cancer progression. Physiologically, ROS are not solely damaging agents; they participate in vital cellular signaling pathways [1]. However, in cancer, a skewed redox balance drives pathological functions such as uncontrolled proliferation and metastasis. Understanding this dual role is crucial for developing therapies that either boost ROS to induce cell death or scavenge excess ROS to protect healthy cells, highlighting a critical distinction between beneficial and detrimental ROS levels [1]. ROS concentrations and their cellular location dictate their impact, making them both instigators and suppressors of tumor growth [4]. This duality means that while low to moderate ROS levels frequently promote tumor growth, survival, and metastasis by acting as signaling molecules, excessively high ROS levels can indeed trigger cell death pathways, paving the way for more nuanced therapeutic strategies [10, 4].

Cancer cells often exhibit elevated baseline ROS levels compared to normal cells, yet they remarkably manage to adapt and survive this persistent oxidative stress. This resilience underscores a critical aspect of cancer biology: how altered ROS homeostasis dictates cell fate, promoting survival or inducing death depending on the cellular context and the degree of oxidative stress [2]. Research in this area suggests that manipulating this delicate balance is a promising strategy for targeted cancer therapies, aiming to push cancer cells beyond their adaptive capacity towards induced death [2].

Here's the thing, therapeutic strategies are moving towards deliberately inducing ROS accumulation to trigger cancer cell death, leveraging the inherent oxidative stress in malignant cells [7]. This approach meticulously outlines various biochemical mechanisms by which these ROS inducers operate, discussing their potential in clinical settings while also addressing the significant physiological challenges of selectively targeting cancer cells without harming healthy tissues [7]. Beyond direct induction, targeting the redox system in cancer therapy involves manipulating the balance between ROS generation and scavenging, a strategy evolving from fundamental molecular mechanisms to active clinical trials. This review details how drugs targeting specific antioxidant enzymes or ROS-producing pathways can selectively kill cancer cells, reflecting a sophisticated understanding of their distinct physiological and biochemical dependencies [6].

What this really means is that exploring the exciting potential of repurposing existing FDA-approved drugs that modulate ROS metabolism for cancer treatment is gaining traction. This strategy highlights specific biochemical pathways these drugs influence, either by increasing ROS to trigger cancer cell death or by dampening ROS to reduce chemotherapy resistance. This approach offers a faster, safer route to new cancer therapies by leveraging known drug safety profiles, significantly accelerating the path to patient benefit [3]. Furthermore, the intricate biochemical relationship between ROS and ferroptosis, an iron-dependent form of regulated cell death, is becoming increasingly clear in the context of cancer. Modulating ROS levels can specifically induce ferroptosis in cancer cells, offering a potent new avenue for targeted therapy by exploiting cancer cells' altered iron metabolism and oxidative vulnerabilities [5].

Cancer Stem Cells (CSCs) are particularly resistant to conventional therapies, and their redox state plays a crucial role in this resistance and their self-renewal capacity [8]. This paper explores the biochemical machinery governing ROS levels in CSCs, illustrating how targeted redox modulation can influence their physiological functions, potentially sensitizing them to existing treatments and overcoming therapy resistance [8]. Another critical area is the complex interplay between ROS signaling and ferroptosis in immune cells within the tumor microenvironment. This detailed understanding of how ROS-mediated events impact immune cell function, either promoting or inhibiting anti-tumor immunity, underscores the profound physiological significance of redox balance for effective immune surveillance and response against cancer [9]. The sum of this knowledge is paving the way for more precise and effective ROS-modulating cancer therapies [10].

Conclusion

Reactive Oxygen Species (ROS) play a critical and complex dual role in cancer, acting as both signaling molecules essential for physiological functions and drivers of pathological processes like proliferation and metastasis when redox balance is skewed. Cancer cells often maintain elevated basal ROS levels but adapt to survive, making ROS homeostasis a key determinant of cell fate. Understanding this delicate balance is crucial for developing effective cancer therapies. Current research highlights several therapeutic avenues. One involves deliberately increasing ROS levels to induce cancer cell death, exploiting the inherent oxidative stress of malignant cells. Conversely, scavenging excess ROS can protect healthy cells or reduce chemotherapy resistance. Drug repurposing offers a promising strategy, leveraging FDA-approved drugs that modulate ROS metabolism. Targeting the redox system, including specific antioxidant enzymes or ROS-producing pathways, aims to selectively kill cancer cells. Furthermore, the interplay between ROS and ferroptosis, an iron-dependent cell death, presents new therapeutic opportunities by exploiting cancer cells’ oxidative vulnerabilities. The redox state of Cancer Stem Cells (CSCs) is also critical, contributing to their therapy resistance, suggesting targeted redox modulation could improve treatment outcomes. Even in the tumor microenvironment, ROS signaling impacts immune cell function and anti-tumor immunity. Overall, precise ROS modulation holds significant potential for future cancer treatments.

References

1. Juan MPA, Antonio BO, Cristina T (2022) .Antioxid Redox Signal 36:129-152.

   , ,

2. Min Z, Jiewen P, Junying G (2022) .Oxid Med Cell Longev 2022:6890250.

   , ,

3. Jin-Ming L, Yi-Chien W, Fang-Wen C (2023) .Oxid Med Cell Longev 2023:8725838.

   , ,

4. Zhaowei H, Yanzhen Z, Zhaoyuan W (2023) .Cell Death Discov 9:445.

   , ,

5. Qing Y, Mengke L, Xiaoxiao L (2023) .Front Pharmacol 14:1257492.

   , ,

6. Junjie L, Yanling W, Qingyi W (2023) .Cell Death Dis 14:359.

   , ,

7. Yuanjie Z, Lu D, Ming L (2023) .Acta Pharm Sin B 13:978-999.

   , ,

8. Francesca F, Elisa L, Alessandro C (2023) .Cell Death Discov 9:416.

   , ,

9. Jiyeon K, Hyoung-Pyo K, Ji-Yoon L (2023) .Cell Death Differ 30:1423-1436.

   , ,

10. Ying L, Dan-Dan A, Jia-Hui M (2023) .Int J Cancer 154:271-285.

    , ,